BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1807 related articles for article (PubMed ID: 32111216)

  • 1. The emerging roles of N6-methyladenosine (m6A) deregulation in liver carcinogenesis.
    Chen M; Wong CM
    Mol Cancer; 2020 Feb; 19(1):44. PubMed ID: 32111216
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mechanism of RNA modification N6-methyladenosine in human cancer.
    Zhou Z; Lv J; Yu H; Han J; Yang X; Feng D; Wu Q; Yuan B; Lu Q; Yang H
    Mol Cancer; 2020 Jun; 19(1):104. PubMed ID: 32513173
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The interplay between m6A RNA methylation and noncoding RNA in cancer.
    Ma S; Chen C; Ji X; Liu J; Zhou Q; Wang G; Yuan W; Kan Q; Sun Z
    J Hematol Oncol; 2019 Nov; 12(1):121. PubMed ID: 31757221
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The potential role of RNA N6-methyladenosine in Cancer progression.
    Wang T; Kong S; Tao M; Ju S
    Mol Cancer; 2020 May; 19(1):88. PubMed ID: 32398132
    [TBL] [Abstract][Full Text] [Related]  

  • 5. KIAA1429 contributes to liver cancer progression through N6-methyladenosine-dependent post-transcriptional modification of GATA3.
    Lan T; Li H; Zhang D; Xu L; Liu H; Hao X; Yan X; Liao H; Chen X; Xie K; Li J; Liao M; Huang J; Yuan K; Zeng Y; Wu H
    Mol Cancer; 2019 Dec; 18(1):186. PubMed ID: 31856849
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of m6A RNA Methylation-Related Genes in Liver Hepatocellular Carcinoma and Their Correlation with Survival.
    Li Y; Qi D; Zhu B; Ye X
    Int J Mol Sci; 2021 Feb; 22(3):. PubMed ID: 33540684
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epigenetic N6-methyladenosine modification of RNA and DNA regulates cancer.
    Liang Z; Kidwell RL; Deng H; Xie Q
    Cancer Biol Med; 2020 Feb; 17(1):9-19. PubMed ID: 32296573
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The functional roles, cross-talk and clinical implications of m6A modification and circRNA in hepatocellular carcinoma.
    Qin S; Mao Y; Chen X; Xiao J; Qin Y; Zhao L
    Int J Biol Sci; 2021; 17(12):3059-3079. PubMed ID: 34421350
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Physio-pathological effects of m6A modification and its potential contribution to melanoma.
    Liao Y; Han P; Zhang Y; Ni B
    Clin Transl Oncol; 2021 Nov; 23(11):2269-2279. PubMed ID: 34105069
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epigenetic regulation of mRNA N6-methyladenosine modifications in mammalian gametogenesis.
    Fang F; Wang X; Li Z; Ni K; Xiong C
    Mol Hum Reprod; 2021 May; 27(5):. PubMed ID: 33823008
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Functions of N6-methyladenosine and its role in cancer.
    He L; Li H; Wu A; Peng Y; Shu G; Yin G
    Mol Cancer; 2019 Dec; 18(1):176. PubMed ID: 31801551
    [TBL] [Abstract][Full Text] [Related]  

  • 12. m6A Regulator-Mediated Methylation Modification Patterns and Tumor Microenvironment Infiltration Characterization in Acute Myeloid Leukemia.
    Du A; Wu X; Gao Y; Jiang B; Wang J; Zhang P; Zhao Q
    Front Immunol; 2021; 12():789914. PubMed ID: 34887874
    [TBL] [Abstract][Full Text] [Related]  

  • 13. RNA m6A modification in liver biology and its implication in hepatic diseases and carcinogenesis.
    Ma W; Wu T
    Am J Physiol Cell Physiol; 2022 Oct; 323(4):C1190-C1205. PubMed ID: 36036444
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potential roles of N6-methyladenosine (m6A) in immune cells.
    Liu C; Yang Z; Li R; Wu Y; Chi M; Gao S; Sun X; Meng X; Wang B
    J Transl Med; 2021 Jun; 19(1):251. PubMed ID: 34103054
    [TBL] [Abstract][Full Text] [Related]  

  • 15. RNA N6-methyladenosine methyltransferase-like 3 promotes liver cancer progression through YTHDF2-dependent posttranscriptional silencing of SOCS2.
    Chen M; Wei L; Law CT; Tsang FH; Shen J; Cheng CL; Tsang LH; Ho DW; Chiu DK; Lee JM; Wong CC; Ng IO; Wong CM
    Hepatology; 2018 Jun; 67(6):2254-2270. PubMed ID: 29171881
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Research Advances in the Roles of N6-Methyladenosine Modification in Ovarian Cancer.
    Zhang Y; Ling Y; Zhou Y; Shi X; Shen F; Zhou J; Chen Y; Yang F; Gu Y; Wang J
    Cancer Control; 2024; 31():10732748241256819. PubMed ID: 38755968
    [TBL] [Abstract][Full Text] [Related]  

  • 17. RNA N6-methyladenosine demethylase FTO promotes breast tumor progression through inhibiting BNIP3.
    Niu Y; Lin Z; Wan A; Chen H; Liang H; Sun L; Wang Y; Li X; Xiong XF; Wei B; Wu X; Wan G
    Mol Cancer; 2019 Mar; 18(1):46. PubMed ID: 30922314
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gene Signatures and Prognostic Values of m6A RNA Methylation Regulators in Ovarian Cancer.
    Han X; Liu J; Cheng G; Cui S
    Cancer Control; 2020; 27(1):1073274820960460. PubMed ID: 32951457
    [TBL] [Abstract][Full Text] [Related]  

  • 19. RNA demethylase ALKBH5 prevents pancreatic cancer progression by posttranscriptional activation of PER1 in an m6A-YTHDF2-dependent manner.
    Guo X; Li K; Jiang W; Hu Y; Xiao W; Huang Y; Feng Y; Pan Q; Wan R
    Mol Cancer; 2020 May; 19(1):91. PubMed ID: 32429928
    [TBL] [Abstract][Full Text] [Related]  

  • 20. N6-methyladenosine links RNA metabolism to cancer progression.
    Dai D; Wang H; Zhu L; Jin H; Wang X
    Cell Death Dis; 2018 Jan; 9(2):124. PubMed ID: 29374143
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 91.